Correlation of thyroid status with severity and mortality of COVID-19 patients

Elae Zaremoghdam1, Ensiye Pordel2, Mostafa Assarroudi3, Saeid Mohammadi4, Ali Kalali Sani5, Hossein Mardanparvar1, Sara Abbasian1*

Abstract

Introduction: Thyroid status because of the expression of angiotensin-converting enzyme-2 (ACE2), which is a functional receptor for coronavirus disease 2019 (COVID-19) in thyroid glands, maybe affects COVID-19 patients’ outcomes.

Objectives: This study aimed to evaluate the correlation of thyroid status with the severity and mortality of COVID-19 patients.

Patients and Methods: In a retrospective cohort study conducted on 521 COVID-19 patients, data were collected by a demographic questionnaire and a checklist of patient outcomes (death/recovery) from the hospital information system (HIS) and analyzed by SPSS version 26 and binary logistic regression. Data about thyroid status were collected from clinical documents and laboratory test data.

Results: Most patients were male (57.2%) with a mean age of 56.12 ± 17.4 years. Seventy-seven patients had a severe stage of disease, and 55 patients died. Twenty-one patients had hyperthyroidism, and 53 patients had hypothyroidism. Results showed that the correlation between hypothyroidism and hypertension with severity and mortality risk of COVID-19 patients was insignificant (P > 0.05).

Conclusion: In this study, we concluded that, thyroid status is not associated with COVID-19 outcomes such as severity or mortality.

Keywords: Thyroid status, COVID-19, Mortality, Severity

Please cite this paper as: Zaremoghdam E, Pordel E, Assarroudi M, Mohammadi S, Kalali Sani A, Mardanparvar H, Abbasian S. Correlation of thyroid status with severity and mortality of COVID-19 patients. J Parathyr Dis. 2022;10:e11161. doi: 10.34172/jpd.2022.11161.

Copyright © 2022 The Author(s); Published by Nican Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Pneumonia caused by the coronavirus family, which first emerged in Wuhan, China, in December 2019, was named by the World Health Organization (WHO) as coronavirus disease 2019 (COVID-19) (1). The international society for classifying of viruses called this new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2). Patients with this disease showed main signs and symptoms, including fever, dry cough, fatigue, body ache, and shortness of breath (2,3). However, clinical findings varied, ranging from asymptomatic pneumonia to severe stages such as respiratory distress, need for mechanical ventilation, and death (4,5). In previous studies, factors such as older age, male gender, underlying disease, and weakness of the immune system were reported as the main affected risk factors for the severity and mortality of patients with COVID-19 (6,7). Thyroid status, including hypothyroidism and hyperthyroidism, is one of the factors that may be affected COVID-19 patients’ outcomes because angiotensin-converting enzyme-2 (ACE2), which is a functional receptor for COVID-19, is expressed in thyroid glands (8,9). Previous studies reported inconsistent results about the impact of hypo and hyperthyroidism on patients with COVID-19 (4,10,11). In this study, we will investigate the effect of hypo and hyperthyroidism on the COVID-19 patient outcomes.

Objectives

Due to the presence of the ACE2 enzyme in the thyroid gland, the function of this gland may affect the results of patients with COVID-19. This study aimed to evaluate the correlation of thyroid status with the severity and mortality of COVID-19 patients.

Patients and Methods

Study design

This retrospective cohort study was conducted on 521 COVID-19 hospitalized patients in Imam Hossein hospital, Tehran, Iran, from February 2020 to June 2021. Inclusion criteria included a definite diagnosis of COVID-19 based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR) results and lung CT-scan findings, and having demographic information in the hospital information system (HIS) of Imam Hossein hospital.
Implication for health policy/practice/research/medical education

In a retrospective cohort study conducted on 521 coronavirus disease 2019 (COVID-19) patients, we found that the correlation between thyroid status and the mortality and severity of COVID-19 patients is not significant.

Hossein hospital. Exclusion criteria included the death of a patient due to any cause except COVID-19. Data about thyroid status was collected from clinical documents and laboratory test data.

Definition of severity and mortality

Patients who needed mechanical ventilation and recovered after a period of treatment were considered severe COVID-19; however, those who died after mechanical ventilation were considered mortality patients.

Statistical analysis

For statistical analyses, SPSS version 26 was used. Quantitative variables were conducted to describe the data center means, and standard deviations were conducted to describe the data distribution. Frequency and percentage were employed to describe the data. Binary regression logistic test was employed to explore the correlation between hypo and hyperthyroidism with the severity and mortality of COVID-19 patients. A \( P \) value less than 0.05 was considered a significant level.

Results

Out of 521 patients who participated in this study, 298 people were male, and 223 were female. The total mean age was 56.12 ± 17.4 years. Seventy-seven patients had a severe stage of disease, and 55 patients died. Twenty-one patients had hyperthyroidism, and 53 had hypothyroidism (Table 1).

Results of binary logistic regression showed no statistically significant correlation between hypothyroidism and hyperthyroidism with mortality risk of COVID-19 patients (Table 2).

Also, the results of binary logistic regression showed that the correlation between hypothyroidism and hyperthyroidism with the severity of COVID-19 was not significant (Table 3).

Discussion

This study is a part of a big study published before (12). In the present study, results showed that hypothyroidism and hyperthyroidism aren't associated with both the severity and outcome of COVID-19 patients, such as death or recovery in the Iranian population. In line with our study, van Gerwen et al showed that hypothyroidism has no statistical correlation with the outcome of COVID-19 patients, such as mortality, hospitalization, or requiring mechanical ventilation (4); Kim et al demonstrated that hypothyroidism and hyperthyroidism not correlated with outcomes of COVID-19 patients (11). Brix et al showed that preexisting hypothyroidism and hyperthyroidism aren't associated with COVID-19 outcomes (13). A cohort study in Iran did not show a correlation between thyroid dysfunction and outcomes of patients with COVID-19 (14). While in contrast with our study Gao et al stated that lower free triiodothyronine (FT3) concentration in patients with COVID-19 is correlated with the severity of the disease and may increase the risk of mortality (10), Rothberger et al showed that lower Free triiodothyronine (T3) in patients who need mechanical ventilation is associate with worse outcomes (15). Moreover, a systematic review and meta-analysis study by Damara et al showed that outcomes and morbidity of COVID-19 patients are associated with the thyroid disorder and hypothyroidism (16). Likewise, Zhang et al stated that patients with thyroid dysfunction who suffer COVID-19 have poor outcomes (17).

Thyroid disorder by several mechanisms may impact the outcomes of COVID-19 patients, such as ACE2 expression, which facilitates entry of COVID-19 virus to the body organs (18), hypercoagulable due to hyperthyroidism which may increase the coagulation factors (19), and protective impact of thyroid hormone on the lung function (20). Each of these mechanisms may affect patients with thyroid disorders suffering from COVID-19 differently and influence their outcomes and severity.

Conclusion

Based on the present study result, we conclude that thyroid status is not associated with COVID-19 severity and mortality; therefore, routine care for patients with thyroid disorders while suffering from COVID-19 seems

| Variables          | Gender, No. (%) | Severity, No. (%) | Mortality, No. (%) | Thyroid status, No. (%) | Age (y), Mean (SD) |
|--------------------|----------------|-------------------|--------------------|-------------------------|-------------------|
|                    | Male           | Severe            | Death              | Hypothyroidism          | 52.16 (17.4)      |
|                    | Female         | Not severe        | Recovery           | Hyperthyroidism         |                   |
|                    | 298 (57.2)     | 77 (14.8)         | 55 (10.6)          | 53 (10.2)               |                   |
|                    | 223 (42.8)     | 444 (85.2)        | 466 (86.4)         | 21 (4)                  |                   |
|                    |                |                   |                    | Normal thyroid          |                   |
|                    |                |                   |                    | 447 (85.8)              |                   |
| Note:              |                |                   |                    |                         |                   |
to be sufficient and additional care is unnecessary.

**Limitations of the study**
Due to the being retrospective study, the incompleteness of the information in the clinical patients’ documents was one of the limitations of the present study; we tried to get the information needed by making phone calls to the patients or their families. Individual, social, psychological, and family differences were uncontrollable variables of the present study that can affect the research results.

**Authors’ contribution**
Conceptualization: EZ and EP; Methodology: HM; Validation: MA; Formal Analysis: AK; Investigation: SA and SM; Resources: EP; HM and SA; Data Curation: SM and EZ; Writing—Original Draft Preparation: SA and EZ; Writing—Review and Editing: AK; EZ and MA; Visualization: SM; Supervision: SA; Project Administration: EZ.

**Conflicts of interest**
The authors declare that they have no conflicts of interest.

**Ethical issues**
The research followed the tenets of the Declaration of Helsinki. Written consent was taken from participants before any intervention. The study is a part of a big research conducted in Imam Hossein hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. A part of this research published before (12).

**Funding/Support**
There is no funding.

**References**
1. Shadkam A, Mahdavi AA, Raoufi M, Mardanparvar H, Fatehi Z. The prevalence of single pulmonary nodules as the first sign of COVID-19 pneumonia in CT scans of patients suspected to COVID-19. J ACADEMIC 2022;37:28-32. doi: 10.3306/AJHS.2022.37.05.28.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi: 10.1016/s0140-6736(20)30183-5.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13. doi: 10.1016/s0140-6736(20)30211-7.
4. van Gerwen M, Alsen M, Little C, Barlow J, Naymagon L, Tremblay D, et al. Outcomes of Patients With Hypothyroidism and COVID-19: A Retrospective Cohort Study. Front Endocrinol (Lausanne). 2020;11:565. doi: 10.3389/fendo.2020.00565.
5. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;323:1406-7. doi: 10.1001/jama.2020.2565.
6. van Gerwen M, Alsen M, Little C, Barlow J, Genden E, Naymagon L, et al. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. J Med Virol. 2021;93:907-15. doi: 10.1002/jmv.26337.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. doi: 10.1016/s0140-6736(20)30566-3.
8. Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43:1027-31. doi: 10.1007/s40618-020-01276-8.
9. Bourgonje AR, Abdulke AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251:228-48. doi: 10.1002/

**Table 2. Assessment of the correlation between hypothyroidism and hyperthyroidism with mortality risk of COVID-19 patients**

| Variables     | Total cases (N=521) | Death (n=55) No. (%) | Recovery (n=466) No. (%) | OR   | Logistic regression 95% CI Lower-Upper | P value |
|---------------|---------------------|----------------------|--------------------------|------|---------------------------------------|---------|
|               |                     |                      |                          |      |                                       |         |
| **Hypothyroidism** |                    |                      |                          |      |                                       |         |
| Yes           | 53                  | 9 (17)               | 44 (83)                  | 1.87 | 0.861-4.089                           | 0.113   |
| No            | 468                 | 46 (9.8)             | 422 (90.2)               |      |                                       |         |
| **Hyperthyroidism** |                  |                      |                          |      |                                       |         |
| Yes           | 21                  | 5 (23.8)             | 16 (76.2)                | 2.81 | 0.968-8.004                           | 0.053   |
| No            | 500                 | 50 (10)              | 450 (90)                 |      |                                       |         |

OR, odds ratio; CI, confidence interval.

**Table 3. Assessment of the correlation between hypothyroidism and hyperthyroidism with the severity of COVID-19 patients**

| Variables     | Total cases (N=521) | Severe (n=77) No. (%) | Not severe (n=444) No. (%) | OR   | Logistic regression 95% CI Lower-Upper | P value |
|---------------|---------------------|-----------------------|-----------------------------|------|---------------------------------------|---------|
|               |                     |                       |                             |      |                                       |         |
| **Hypothyroidism** |                    |                       |                             |      |                                       |         |
| Yes           | 53                  | 8 (15.1)              | 45 (84.9)                  | 1.028| 0.465 – 2.275                        | 0.964   |
| No            | 468                 | 69 (14.7)             | 399 (85.3)                 |      |                                       |         |
| **Hyperthyroidism** |                  |                       |                             |      |                                       |         |
| Yes           | 21                  | 2 (9.5)               | 19 (90.5)                  | 0.596| 0.136 – 2.614                        | 0.439   |
| No            | 500                 | 77 (14.8)             | 444 (85.2)                 |      |                                       |         |

OR, odds ratio; CI, confidence interval.
10. Gao W, Guo W, Guo Y, Shi M, Dong G, Wang G, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19. J Endocrinol Invest. 2021;44:1031-40. doi: 10.1007/s40618-020-01460-w.

11. Kim SY, Yoo DM, Min CY, Choi HG. The Effects of Previous Thyroid Disease on the Susceptibility to, Morbidity of, and Mortality Due to COVID-19: A Nationwide Cohort Study in South Korea. J Clin Med. 2021;10. doi: 10.3390/jcm10163522.

12. Moradkhani S, Chegeni M, Mousapour R, Karrabi K, Charebakhshi F, Safa K, et al. Correlation Of Initial Chest CT Finding of COVID-19 Patients with Their Death Risk. JCMR. 2021;12:144-7. doi: 10.5455/jcmr.2021.12.04.23.

13. Brix TH, Hegedüs L, Hallás J, Lund LC. Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism. Lancet Diabetes Endocrinol. 2021;9:197-9. doi: 10.1016/s2213-8587(21)00028-0.

14. Daraei M, Hasibi M, Abdollahi H, Mirabdolhagh Hazaveh M, Zebardast J, Hajnoori M, et al. Possible role of hypothyroidism in the prognosis of COVID-19. Intern Med J. 2020;50:1410-2. doi: 10.1111/imj.15000.

15. Rothberger GD, Valestra PK, Knight K, Desai AK, Calixte R, Shapiro LE. Low Free T(3) Is Associated With Worse Outcomes in Patients in the ICU Requiring Invasive Mechanical Ventilation. J Intensive Care Med. 2021;36:313-8. doi: 10.1177/0885066619890822.

16. Damara FA, Muchamad GR, Ikhsani R, Hendro, Syafiyah AH, Bashari MH. Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021;15:102312. doi: 10.1016/j.dsx.2021.102312.

17. Zhang Y, Lin F, Tu W, Zhang J, Choudhry AA, Ahmed O, et al. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19. Mol Cell Endocrinol. 2021;521:111097. doi: 10.1016/j.mce.2020.111097.

18. Kumari K, Chainy GBN, Subudhi U. Prospective role of thyroid disorders in monitoring COVID-19 pandemic. Heliyon. 2020;6:e05712. doi: 10.1016/j.heliyon.2020.e05712.

19. Ordookhani A, Burman KD. Hemostasis in Overt and Subclinical Hyperthyroidism. Int J Endocrinol Metab. 2017;15:e44157. doi: 10.5812/ijem.44157.

20. Yu G, Tzouvelekis A, Wang R, Herazo-Mayo JD, Ibarra GH, Srivastava A, et al. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat Med. 2018;24:39-49. doi: 10.1038/nm.4447.